Novo Nordisk A/S (NVO) Company Profile
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.
News about NVO
Is Baidu Inc (ADR) a Buy?
Chinese search giant Baidu (NASDAQ:BIDU) went public in 2005. After stumbling out of the IPO gate, it experienced the type of run-up that can create dynastic wealth for patient investors. Between early 2006 and mid-2011, shares of the company advan...Read More>>>
$1.90 Billion in Sales Expected for Huntington Ingalls Industries (HII) This Quarter
Wall Street analysts expect that Huntington Ingalls Industries (NYSE:HII) will post $1.90 billion in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Huntington Ingalls Industries’ earni...Read More>>>
Caregiver Crunch? No Problem, This Is How Tech-Savvy Millennials Will Care For Aging Baby Boomers
&l;p&g;&l;img class=&q;size-full wp-image-213&q; src=&q;http://blogs-images.forbes.com/josephcoughlin/files/2018/05/shutterstock_769914709.jpg?width=960&q; alt=&q;&q; data-height=&q;668&q; data-width=&q;1000&q;&g; Millennials will care for Baby Boome...Read More>>>
Yintech: Becoming More Diversified And Predictable After Rough 2017
Thesis As a very small cap Chinese-listed ADR, Yintech (YIN) continues to have little coverage from analysts or otherwise. After a rough 2017 where its rapidly falling comparisons make it a certainty to screen out, the company's transition is not bei...Read More>>>
Monro Inc. (MNRO) Q4 2018 Earnings Conference Call Transcript
Image source: The Motley Fool. Monro, Inc. (NASDAQ:MNRO)Q4 2018 Earnings Conference CallMay 21, 2018, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Maureen Mulholland -- Vice President, General C...Read More>>>